Z. Beketova
Geographical burden of NAFLD: a review
Over the past few decades, non-alcoholic fatty liver disease (NAFLD) has become a growing problem, alongside the increasing rates of obesity and type 2 diabetes.
Read MoreGeographical burden of NAFLD: a reviewGlobal research on fatty liver disease: a review
In this study, a large, global, multidisciplinary panel discussed priorities within the field of fatty liver disease, including its burden, policies surrounding the issue and treatment options.
Read MoreGlobal research on fatty liver disease: a reviewManaging Hepatocellular Carcinoma in NAFLD: a review
Currently, there are rising levels of non-alcoholic fatty liver disease (NAFLD). With this, comes a concurrent increase in hepatocellular carcinoma (HCC) cases.
Read MoreManaging Hepatocellular Carcinoma in NAFLD: a reviewThe new paradigm of cardiometabolic syndrome: a review
Cardiometabolic syndrome (CMS) involves a complex interplay of many issues, involving obesity, metabolic dysregulation, cardiovascular disease, insulin resistance and more. This condition extends to clinical implications including non-alcoholic fatty liver disease (NAFLD) as well as cancer and sleep apnoea.
Read MoreThe new paradigm of cardiometabolic syndrome: a review
International NASH Day 2023: Empowering Healthcare Professionals
On International NASH Day 2023, PanNASH amplifies the importance of NASH awareness, education, and action. Learn about the complex multisystem nature of NASH, the potential of PPAR agonists in NASH management, and the role of healthcare professionals in delivering effective, patient-centered care. Discover how PanNASH resources are empowering the medical community and join us in taking action against NASH.
Read MoreInternational NASH Day 2023: Empowering Healthcare ProfessionalsAnti-inflammatory and Antifibrotic Targets for the Treatment of NASH: a Review
Generally, NASH and fibrosis correlate with the development of cirrhosis and other negative clinical outcomes. Treatments often aim to target inflammation, fibrosis, cell injury or metabolic dysregulation.
Read MoreAnti-inflammatory and Antifibrotic Targets for the Treatment of NASH: a ReviewCardiovascular Disease in MAFLD Versus NAFLD: A Review
Changing the terminology from NAFLD, non-alcoholic fatty liver disease, to MAFLD, metabolic dysfunction-associated fatty liver disease, has been an ongoing debate. MAFLD is based upon an individual having hepatic steatosis, as well as either type 2 diabetes mellitus, obesity (or being overweight) or if at a normal weight, two or more metabolic risk abnormalities.
Read MoreCardiovascular Disease in MAFLD Versus NAFLD: A ReviewCosts of Care for Non-Alcoholic Steatohepatitis in the United States: A Review
The rising healthcare costs of NASH highlight the need for early intervention. Higher FIB-4 scores correlate with increased healthcare expenses. Early-stage intervention can reduce the burden on patients and the healthcare system.
Read MoreCosts of Care for Non-Alcoholic Steatohepatitis in the United States: A ReviewNon-Invasive Tests and Their Cut-Offs for Assessing Fibrosis: A Review
Heterogeneity in cut-off points for non-invasive fibrosis tests impacts NAFLD risk stratification. Standardized guidelines could improve consistency and accuracy in identifying patients requiring specialist care.
Read MoreNon-Invasive Tests and Their Cut-Offs for Assessing Fibrosis: A ReviewPhysician-Stated vs Clinically-Derived Reference Fibrosis Score in NASH: A Review
Physicians often underestimate or overestimate fibrosis severity in NASH, leading to concerns about appropriate treatment. Standardized interpretations of risk stratification tools are needed.
Read MorePhysician-Stated vs Clinically-Derived Reference Fibrosis Score in NASH: A ReviewNon-Invasive Tests to Stratify NAFLD Based on Liver-Related Events: A Review
FIB4 and VCTE show promise in predicting prognosis for NAFLD patients. These non-invasive tests offer an alternative to liver biopsies for risk stratification. Quick and easily prescribed, they can streamline referrals and specialized management. A sequential algorithm with FIB4 and VCTE may improve NAFLD care.
Read MoreNon-Invasive Tests to Stratify NAFLD Based on Liver-Related Events: A ReviewNAFLD and NASH Occurring After Liver Transplantation: A Review
Recurrence of NASH/NAFLD after liver transplantation requires attention. Factors include weight gain, post-transplant diabetes, and immunosuppressant drugs. Donor-related genetic risk factors also contribute. A multidisciplinary approach is essential for prevention and management.
Read MoreNAFLD and NASH Occurring After Liver Transplantation: A Review
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES